Logo image of CYCC

CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Fundamental Analysis

NASDAQ:CYCC - Nasdaq - US23254L8019 - Common Stock - Currency: USD

2.32  -0.43 (-15.64%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CYCC. CYCC was compared to 562 industry peers in the Biotechnology industry. CYCC may be in some trouble as it scores bad on both profitability and health. CYCC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

CYCC had negative earnings in the past year.
In the past year CYCC has reported a negative cash flow from operations.
In the past 5 years CYCC always reported negative net income.
In the past 5 years CYCC always reported negative operating cash flow.
CYCC Yearly Net Income VS EBIT VS OCF VS FCFCYCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

CYCC has a Return On Assets of -273.86%. This is amonst the worse of the industry: CYCC underperforms 93.59% of its industry peers.
Industry RankSector Rank
ROA -273.86%
ROE N/A
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CYCC Yearly ROA, ROE, ROICCYCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

CYCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCC Yearly Profit, Operating, Gross MarginsCYCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

0

2. Health

2.1 Basic Checks

CYCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CYCC has more shares outstanding
CYCC has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CYCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CYCC Yearly Shares OutstandingCYCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CYCC Yearly Total Debt VS Total AssetsCYCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -60.37, we must say that CYCC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -60.37, CYCC is doing worse than 94.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -60.37
ROIC/WACCN/A
WACC10.02%
CYCC Yearly LT Debt VS Equity VS FCFCYCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 0.59 indicates that CYCC may have some problems paying its short term obligations.
The Current ratio of CYCC (0.59) is worse than 92.70% of its industry peers.
A Quick Ratio of 0.59 indicates that CYCC may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.59, CYCC is doing worse than 92.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.59
CYCC Yearly Current Assets VS Current LiabilitesCYCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

4

3. Growth

3.1 Past

CYCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.15%, which is quite impressive.
The Revenue for CYCC has decreased by -89.69% in the past year. This is quite bad
EPS 1Y (TTM)75.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.55%
Revenue 1Y (TTM)-89.69%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 36.35% on average over the next years. This is a very strong growth
CYCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 385.15% yearly.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%

3.3 Evolution

CYCC Yearly Revenue VS EstimatesCYCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CYCC Yearly EPS VS EstimatesCYCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1K -2K -3K

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CYCC. In the last year negative earnings were reported.
Also next year CYCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCC Price Earnings VS Forward Price EarningsCYCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCC Per share dataCYCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as CYCC's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

0

5. Dividend

5.1 Amount

CYCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CYCLACEL PHARMACEUTICALS INC

NASDAQ:CYCC (5/14/2025, 8:00:00 PM)

2.32

-0.43 (-15.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-12 2025-08-12
Inst Owners6.51%
Inst Owner Change1.4%
Ins Owners0.91%
Ins Owner Change0%
Market Cap884.38M
Analysts43.33
Price TargetN/A
Short Float %1.45%
Short Ratio0.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-38.18%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.96%
Min Revenue beat(2)-100%
Max Revenue beat(2)96.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20567.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.49
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -273.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.59
Altman-Z -60.37
F-Score2
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.55%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue 1Y (TTM)-89.69%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%
EBIT growth 1Y52.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.41%
OCF growth 3YN/A
OCF growth 5YN/A